Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12235815 | 0.91 | KMT2A (0.64) | KMT2AEPHX2GAAFABP5FABP7 | |
| SCHEMBL118052 | 0.87 | EPHX2 (0.63) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29401210 | 0.87 | EPHX2 (0.63) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29561956 | 0.87 | EPHX2 (0.63) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL13187755 | 0.86 | EPHX2 (0.60) | KMT2AEPHX2GAAFABP5FABP7 | |
| SCHEMBL14898524 | 0.86 | KMT2A (0.59) | KMT2AEPHX2GAAFABP5FABP7 | |
| SCHEMBL114404 | 0.84 | KMT2A (0.60) | KMT2AEPHX2GAAFABP5FABP7 | |
| SCHEMBL7913189 | 0.84 | EPHX2 (0.59) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL22635803 | 0.84 | KMT2A (0.56) | KMT2AEPHX2GAAFABP5CASP3 | |
| SCHEMBL346077 | 0.82 | KMT2A (0.52) | KMT2AEPHX2GAAFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247541-B1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | PEPTILOGICS INC (US) | 2024-08-28 | — | — | EP | claimed |
| US-20240002431-A1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | PEPTILOGICS, INC. (US) | 2024-01-04 | — | — | US | claimed |
| EP-4247541-A1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | Peptilogics, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| WO-2022109456-A1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | LEE FRANCIS (US) | 2022-05-27 | — | — | WO | claimed |
| EP-3728304-B1 | SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES | BACHEM HOLDING AG (CH) | 2025-02-12 | — | — | EP | disclosed |
| US-20240344123-A1 | METHODS AND APPARATUSES FOR GENERATING PEPTIDES BY SYNTHESIZING A PORTION OF A DESIGN SPACE TO IDENTIFY PEPTIDES HAVING NON-CANONICAL AMINO ACIDS | PEPTILOGICS, INC. (US) | 2024-10-17 | — | — | US | disclosed |
| EP-4247541-B1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | PEPTILOGICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12006541-B2 | Methods and apparatuses for generating peptides by synthesizing a portion of a design space to identify peptides having non-canonical amino acids | PEPTILOGICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240002431-A1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | PEPTILOGICS, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-20240002431-A1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | PEPTILOGICS, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4247541-A1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | Peptilogics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4247541-A1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | Peptilogics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-1549667-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| US-20040253225-A1 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2004-12-16 | — | — | US | disclosed |
| WO-2004065407-A2 | IMPROVED GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004031221-A9 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004031221-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031218-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031219-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031220-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040253225-A1 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | GRPR, MLNR, NPBWR1 | KMT2A 4045/4885EPHX2 3747/4885GAA 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.